{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:17:25Z","timestamp":1792045045139,"version":"4.4.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2016YFC1303503"],"award-info":[{"award-number":["2016YFC1303503"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003347","name":"Fudan University","doi-asserted-by":"publisher","award":["SKLGE-2119"],"award-info":[{"award-number":["SKLGE-2119"]}],"id":[{"id":"10.13039\/501100003347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.canlet.2021.09.012","type":"journal-article","created":{"date-parts":[[2021,9,11]],"date-time":"2021-09-11T10:38:26Z","timestamp":1631356706000},"page":"32-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"special_numbering":"C","title":["IDO1\/TDO dual inhibitor RY103 targets Kyn-AhR pathway and exhibits preclinical efficacy on pancreatic cancer"],"prefix":"10.1016","volume":"522","author":[{"given":"Heng","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zikang","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengnan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weirui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leilei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxiang","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongrui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2021.09.012_bib1","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S2468-1253(19)30347-4","article-title":"The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"4","author":"Collaborators","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.canlet.2021.09.012_bib2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S2468-1253(17)30046-8","article-title":"Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial","volume":"2","author":"Bachet","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.canlet.2021.09.012_bib3","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1158\/1078-0432.CCR-19-1864","article-title":"Neoadjuvant therapy remodels the pancreatic cancer microenvironment via depletion of protumorigenic immune cells","volume":"26","author":"Mota Reyes","year":"2020","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2021.09.012_bib4","doi-asserted-by":"crossref","DOI":"10.4161\/21624011.2014.950171","article-title":"The pancreatic cancer microenvironment: an immunologic battleground","volume":"3","author":"Pillarisetty","year":"2014","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2021.09.012_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2017.05.010","article-title":"SnapShot: immune checkpoint inhibitors","volume":"31","author":"Abril-Rodriguez","year":"2017","journal-title":"Canc. Cell"},{"key":"10.1016\/j.canlet.2021.09.012_bib6","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1042\/bj2300635","article-title":"Human indolylamine 2,3-dioxygenase. Its tissue distribution, and characterization of the placental enzyme","volume":"230","author":"Yamazaki","year":"1985","journal-title":"Biochem. J."},{"key":"10.1016\/j.canlet.2021.09.012_bib7","doi-asserted-by":"crossref","DOI":"10.1177\/1178646917691938","article-title":"Kynurenine pathway of tryptophan metabolism: regulatory and functional aspects","volume":"10","author":"Badawy","year":"2017","journal-title":"Int. J. Tryptophan Res."},{"key":"10.1016\/j.canlet.2021.09.012_bib8","doi-asserted-by":"crossref","DOI":"10.4161\/21624011.2014.968480","article-title":"Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer","volume":"4","author":"Hjortso","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2021.09.012_bib9","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41573-019-0016-5","article-title":"Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond","volume":"18","author":"Platten","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2021.09.012_bib10","first-page":"673","article-title":"Cancer immunotherapy by targeting IDO1\/TDO and their downstream effectors","volume":"5","author":"Platten","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2021.09.012_bib11","first-page":"710","article-title":"Expression and prognostic value of indoleamine 2,3-dioxygenase in pancreatic cancer, chin","volume":"130","author":"Zhang","year":"2017","journal-title":"Med. J."},{"key":"10.1016\/j.canlet.2021.09.012_bib12","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.prp.2018.02.016","article-title":"Indoleamine 2, 3-dioxygenase and B7-H1 expressions as prognostic and follow-up markers in human pancreatic carcinoma","volume":"214","author":"Wang","year":"2018","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.canlet.2021.09.012_bib13","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/ijc.30760","article-title":"Tumor cell expression of immune inhibitory molecules and tumor-infiltrating lymphocyte count predict cancer-specific survival in pancreatic and ampullary cancer","volume":"141","author":"Sideras","year":"2017","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.canlet.2021.09.012_bib14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13046-021-01847-4","article-title":"What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past","volume":"40","author":"Yao","year":"2021","journal-title":"J. Exp. Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2021.09.012_bib15","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.tips.2017.11.007","article-title":"Targeting the IDO1\/TDO2-KYN-AhR pathway for cancer immunotherapy - challenges and opportunities","volume":"39","author":"Cheong","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.canlet.2021.09.012_bib16","doi-asserted-by":"crossref","first-page":"6059","DOI":"10.1038\/sj.onc.1205633","article-title":"Increased arylhydrocarbon receptor expression offers a potential therapeutic target for pancreatic cancer","volume":"21","author":"Koliopanos","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2021.09.012_bib17","article-title":"Trial watch: IDO inhibitors in cancer therapy","volume":"3","author":"Vacchelli","year":"2014","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2021.09.012_bib18","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13045-018-0644-y","article-title":"Targeting the IDO1 pathway in cancer: from bench to bedside","volume":"11","author":"Liu","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2021.09.012_bib19","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1172\/JCI124077","article-title":"IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma","volume":"129","author":"Blair","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2021.09.012_bib20","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s11596-010-0354-3","article-title":"1-MT enhances potency of tumor cell lysate-pulsed dendritic cells against pancreatic adenocarcinoma by downregulating the percentage of tregs","volume":"30","author":"Li","year":"2010","journal-title":"J. Huazhong Univ. Sci. Technol. - Med. Sci."},{"key":"10.1016\/j.canlet.2021.09.012_bib21","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/s41467-017-01651-9","article-title":"Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression","volume":"8","author":"Lu","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2021.09.012_bib22","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1158\/2326-6066.CIR-14-0214","article-title":"Salmonella-based therapy targeting indoleamine 2,3-dioxygenase coupled with enzymatic depletion of tumor hyaluronan induces complete regression of aggressive pancreatic tumors","volume":"3","author":"Manuel","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.canlet.2021.09.012_bib23","first-page":"EC01","article-title":"Risk stratification in paragangliomas with PASS (pheochromocytoma of the adrenal gland scaled score) and immunohistochemical markers","volume":"10","author":"Kulkarni","year":"2016","journal-title":"J. Clin. Diagn. Res."},{"key":"10.1016\/j.canlet.2021.09.012_bib24","first-page":"3079","article-title":"Effects of artonin e on migration and invasion capabilities of human lung cancer cells","volume":"33","author":"Plaibua","year":"2013","journal-title":"Anticancer Res."},{"key":"10.1016\/j.canlet.2021.09.012_bib25","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/s13046-019-1318-5","article-title":"A positive feedback between IDO1 metabolite and COL12A1 via MAPK pathway to promote gastric cancer metastasis","volume":"38","author":"Xiang","year":"2019","journal-title":"J. Exp. Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2021.09.012_bib26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nature10491","article-title":"An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor","volume":"478","author":"Opitz","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2021.09.012_bib27","doi-asserted-by":"crossref","first-page":"622467","DOI":"10.3389\/fimmu.2020.622467","article-title":"GBP1 facilitates indoleamine 2,3-dioxygenase extracellular secretion to promote the malignant progression of lung cancer","volume":"11","author":"Meng","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2021.09.012_bib28","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1158\/0008-5472.CAN-15-2011","article-title":"A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer","volume":"75","author":"D'Amato","year":"2015","journal-title":"Can. Res."},{"key":"10.1016\/j.canlet.2021.09.012_bib29","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/toxsci\/kfz125","article-title":"AhR activation in pharmaceutical development: applying liver gene expression biomarker thresholds to identify doses associated with tumorigenic risks in rats","volume":"171","author":"Qin","year":"2019","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.canlet.2021.09.012_bib30","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.1158\/0008-5472.CAN-15-3502","article-title":"Nutritional stress induced by tryptophan-degrading enzymes results in ATF4-dependent reprogramming of the amino acid transporter profile in tumor cells","volume":"76","author":"Timosenko","year":"2016","journal-title":"Can. Res."},{"key":"10.1016\/j.canlet.2021.09.012_bib31","article-title":"LSL-KrasG12D; LSL-Trp53R172H\/+; Ink4flox\/+; Ptf1\/p48-Cre mice are an applicable model for locally invasive and metastatic pancreatic cancer","volume":"12","author":"Ma","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.canlet.2021.09.012_bib32","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.cell.2020.07.038","article-title":"IL4I1 is a metabolic immune checkpoint that activates the AHR and promotes tumor progression","volume":"182","author":"Sadik","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2021.09.012_bib33","doi-asserted-by":"crossref","first-page":"12150","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2021.09.012_bib34","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.celrep.2015.08.077","article-title":"Tumor-expressed IDO recruits and activates MDSCs in a treg-dependent manner","volume":"13","author":"Holmgaard","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2021.09.012_bib35","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ijbiomac.2019.06.139","article-title":"Immunomodulatory and antioxidant effects of pomegranate peel polysaccharides on immunosuppressed mice","volume":"137","author":"Wu","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.canlet.2021.09.012_bib36","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41417-020-0183-x","article-title":"Revisiting the role of CD4(+) T cells in cancer immunotherapy-new insights into old paradigms","volume":"28","author":"Tay","year":"2021","journal-title":"Canc. Gene Ther."},{"key":"10.1016\/j.canlet.2021.09.012_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22010387","article-title":"How the AHR became important in cancer: the role of chronically active AHR in cancer aggression","volume":"22","author":"Wang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2021.09.012_bib38","first-page":"38","article-title":"An increased level of aryl hydrocarbon receptor in patients with pancreatic cancer, Middle East","volume":"11","author":"Masoudi","year":"2019","journal-title":"J Dig Dis"},{"key":"10.1016\/j.canlet.2021.09.012_bib39","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1021\/tx5005198","article-title":"Omeprazole inhibits pancreatic cancer cell invasion through a nongenomic aryl hydrocarbon receptor pathway","volume":"28","author":"Jin","year":"2015","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.canlet.2021.09.012_bib40","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/ijc.32733","article-title":"NO(*)\/RUNX3\/kynurenine metabolic signaling enhances disease aggressiveness in pancreatic cancer","volume":"146","author":"Wang","year":"2019","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.canlet.2021.09.012_bib41","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/hpb.12201","article-title":"A biological basis for depression in pancreatic cancer","volume":"16","author":"Botwinick","year":"2014","journal-title":"HPB"},{"key":"10.1016\/j.canlet.2021.09.012_bib42","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1186\/1471-2407-14-738","article-title":"Elevation of MMP-9 and IDO induced by pancreatic cancer cells mediates natural killer cell dysfunction","volume":"14","author":"Peng","year":"2014","journal-title":"BMC Canc."},{"key":"10.1016\/j.canlet.2021.09.012_bib43","first-page":"9","article-title":"Influence of indoleamine-2,3-dioxygenase and its metabolite kynurenine on gammadelta T cell cytotoxicity against ductal pancreatic adenocarcinoma cells","author":"Jonescheit","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2021.09.012_bib44","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41590-017-0022-x","article-title":"Myeloid-derived suppressor cells coming of age","volume":"19","author":"Veglia","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2021.09.012_bib45","doi-asserted-by":"crossref","first-page":"6705","DOI":"10.1021\/acs.jmedchem.9b00662","article-title":"Discovery of clinical candidate (1r,4r)-4-((R)-2-((S)-6-Fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl)cyc lohexan-1-ol (navoximod), a potent and selective inhibitor of indoleamine 2,3-dioxygenase 1","volume":"62","author":"Kumar","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.canlet.2021.09.012_bib46","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1158\/1535-7163.MCT-09-0628","article-title":"Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors","volume":"9","author":"Koblish","year":"2010","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.canlet.2021.09.012_bib47","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1182\/blood-2009-09-246124","article-title":"Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity","volume":"115","author":"Liu","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2021.09.012_bib48","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1158\/1535-7163.MCT-17-1104","article-title":"Characterization of the selective indoleamine 2,3-dioxygenase-1 (IDO1) catalytic inhibitor EOS200271\/PF-06840003 supports IDO1 as a critical resistance mechanism to PD-(l)1 blockade therapy","volume":"17","author":"Gomes","year":"2018","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.canlet.2021.09.012_bib49","doi-asserted-by":"crossref","first-page":"9869","DOI":"10.1038\/s41598-018-28238-8","article-title":"1-Methyl-D-tryptophan reduces tumor CD133(+) cells, wnt\/beta-catenin and NF-kappabetap65 while enhances lymphocytes NF-kappabeta2, STAT3, and STAT4 pathways in murine pancreatic adenocarcinoma","volume":"8","author":"Alahdal","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2021.09.012_bib50","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ejmech.2018.11.010","article-title":"Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase","volume":"162","author":"Winters","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.canlet.2021.09.012_bib51","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.bmc.2019.02.014","article-title":"4,6-Substituted-1H-Indazoles as potent IDO1\/TDO dual inhibitors","volume":"27","author":"Yang","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.canlet.2021.09.012_bib52","doi-asserted-by":"crossref","first-page":"9161","DOI":"10.1021\/acs.jmedchem.9b01079","article-title":"N-Benzyl\/Aryl substituted tryptanthrin as dual inhibitors of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase","volume":"62","author":"Yang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.canlet.2021.09.012_bib53","first-page":"24","article-title":"Discovery and characterisation of dual inhibitors of tryptophan 2,3-dioxygenase (TDO2) and indoleamine 2,3-dioxygenase 1 (IDO1) using virtual screening","author":"Sari","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.canlet.2021.09.012_bib54","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.bcp.2019.07.011","article-title":"Synthesis and in vivo antitumor evaluation of an orally active potent phosphonamidate derivative targeting IDO1\/IDO2\/TDO","volume":"168","author":"Feng","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.canlet.2021.09.012_bib55","doi-asserted-by":"crossref","first-page":"127159","DOI":"10.1016\/j.bmcl.2020.127159","article-title":"Synthesis of novel tryptanthrin derivatives as dual inhibitors of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase","volume":"30","author":"Li","year":"2020","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.canlet.2021.09.012_bib56","doi-asserted-by":"crossref","first-page":"111985","DOI":"10.1016\/j.ejmech.2019.111985","article-title":"Design, synthesis and biological evaluation of indole-2-carboxylic acid derivatives as IDO1\/TDO dual inhibitors","volume":"188","author":"Cui","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.canlet.2021.09.012_bib57","doi-asserted-by":"crossref","first-page":"112703","DOI":"10.1016\/j.ejmech.2020.112703","article-title":"Discovery and structure-activity relationship studies of 1-aryl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione derivatives as potent dual inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and trytophan 2,3-dioxygenase (TDO)","volume":"207","author":"Pan","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.canlet.2021.09.012_bib58","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000870","article-title":"Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors","volume":"8","author":"Naing","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.canlet.2021.09.012_bib59","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.it.2016.01.002","article-title":"IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance","volume":"37","author":"Munn","year":"2016","journal-title":"Trends Immunol."},{"key":"10.1016\/j.canlet.2021.09.012_bib60","first-page":"11","article-title":"Gemcitabine combination nano therapies for pancreatic cancer","author":"Samanta","year":"2019","journal-title":"Pharmaceutics"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521004596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521004596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:04:34Z","timestamp":1777550674000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383521004596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":60,"alternative-id":["S0304383521004596"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2021.09.012","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IDO1\/TDO dual inhibitor RY103 targets Kyn-AhR pathway and exhibits preclinical efficacy on pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2021.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}